Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy

被引：129

作者：

Heep, M

Kist, M

Strobel, S

Beck, D

Lehn, N

机构：

[1] Univ Freiburg, Inst Med Microbiol & Hyg, D-79104 Freiburg, Germany

[2] Uniklin Regensburg, Inst Med Mikrobiol, D-93053 Regensburg, Germany

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2000年 / 19卷 / 07期

关键词：

D O I：

10.1007/s100960000288

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In a study to determine secondary resistance among Helicobacter pylori isolates, gastroenterologists from several German cities submitted over a 3-year period to centre A (Regensburg) or centre B (Freiburg) gastric biopsies from patients in whom one or more therapies to eradicate Helicobacter pylori had failed. Rates of resistance among the collections of 302 (centre A) and 252 (centre B) isolates were, respectively, as follows: to metronidazole, 75% and 66%; to clarithromycin, 58% and 49%; to amoxicillin, 0%; to ciprofloxacin, 9%; to doxycycline, 0%; and to rifampin, 0%. Resistance to clarithromycin was associated with metronidazole resistance in 89% and 85% of the isolates in centre A and centre B, respectively.

引用

收藏

页码：538 / 541

页数：4

相关论文

共 12 条

[1]

Breuer T, 1999, AM J GASTROENTEROL, V94, P725, DOI 10.1111/j.1572-0241.1999.00943.x

[2] Amoxycillin tolerance in Helicobacter pylori [J].

Dore, MP ;

Osato, MS ;

Realdi, G ;

Mura, I ;

Graham, DY ;

Sepulveda, AR .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :47-54

[3] Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin [J].

García-Arata, MI ;

Baquero, F ;

de Rafael, L ;

de Argila, CM ;

Gisbert, JP ;

Bermejo, F ;

Boixeda, D ;

Cantón, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :374-376

[4] Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: Importance of medium, inoculum, and incubation time [J].

Hartzen, SH ;

Andersen, LP ;

Bremmelgaard, A ;

Colding, H ;

Arpi, M ;

Kristiansen, J ;

Justesen, T ;

Espersen, F ;

FrimodtMoller, N ;

Bonnevie, O .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (12) :2634-2639

[5] Rifampin and rifabutin resistance mechanism in Helicobacter pylori [J].

Heep, M ;

Beck, D ;

Bayerdörffer, E ;

Lehn, N .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1497-1499

[6]

Houben MHMG, 1999, ALIMENT PHARM THER, V13, P1047

[7]

Malfertheiner P, 1997, GUT, V41, P8

[8] Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial:: the MACH 2 study [J].

Mégraud, F ;

Lehn, N ;

Lind, T ;

Bayerdörffer, E ;

O'Morain, C ;

Spiller, R ;

Unge, P ;

Van Zanten, SV ;

Wrangstadh, M ;

Burman, CF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2747-2752

[9] NUCLEOTIDE-SEQUENCE OF THE GYRA GENE AND CHARACTERIZATION OF CIPROFLOXACIN-RESISTANT MUTANTS OF HELICOBACTER-PYLORI [J].

MOORE, RA ;

BECKTHOLD, B ;

WONG, S ;

KUREISHI, A ;

BRYAN, LE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (01) :107-111

[10] Treatment of antibiotic-resistant Helicobacter pylori infection [J].

Perri, F ;

Festa, V ;

Andriulli, A .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (01) :53-53